Register for free to
view the full innovation profile.
A unique opportunity to study disease progression and examine various therapies and nutraceuticals that are for treating obesity, MetS, diabetes and other related CV diseases.
About
Description: Metabolic syndrome (MetS) is a combination of metabolic risk factors that increase the risk of developing cardiovascular (CV) disease and type-2 diabetes. Currently, it is estimated that up to 25% of the population in USA suffers from MetS. However, the cause of MetS is not completely understood and very few models exist to study this disease. A University of Guelph researcher has developed a novel mouse model, which offers a unique opportunity to study disease progression, and examine various therapies and nutraceuticals that are indicated for treating obesity, MetS, diabetes, and other related CV diseases. Mouse Characteristics: - Increased body weight gain over time - Higher blood glucose - Insulin resistance - Higher blood VLDL (the bad cholesterol) and triglycerides levels - Lower metabolic rate - Fatty liver and increased fat deposition in muscles and skin Applications: - A unique animal model to study the molecular mechanism of MetS - A good research tool to test the effects of various drugs and nutraceuticals on prevention and/or progression of MetS, diabetes, and other CV diseases Development Status: Knockout mouse generated Mouse growth and development characteristics well characterized Patent Status: Issued patent on knock-out (US 6,777,216) License Status: Seeking for licensee and research partners